RuncheyResearch

Archived research. Equity forecasting is part of the Runchey Research archive (methodology era 1) and is no longer actively updated. Everything remains published at its original URL. Browse the archive

Back to Forecasting

SMMT Forecast Markets

Summit Therapeutics, Inc.

7
Active Markets
57%
Avg Probability
Price Above Value
Mar 17, 2026

Our prediction ensemble identifies elevated risk at current levels.

7 markets analyzedConfidence: MEDIUM
Read Full Thesis

All Markets

7 markets

Will the FDA approve ivonescimab (HARMONi BLA) by the November 14, 2026 PDUFA date?

Active
32%
Likely No
82% agreement
Nov 30, 2026
IG: 1.00

Will HARMONi-3 squamous interim PFS analysis report statistically significant results by Q3 2026?

Active
60%
Likely Yes
82% agreement
Sep 30, 2026
IG: 0.80

Will Summit report interim OS data from HARMONi-3 before the November 14 PDUFA date?

Active
52%
Likely Yes
78% agreement
Nov 14, 2026
IG: 0.80

Will SMMT maintain a market capitalization above $10B through September 2026?

Active
55%
Likely Yes
80% agreement
Oct 15, 2026
IG: 0.64

Will Summit Therapeutics maintain at least 4 quarters of cash runway through Q2 2026?

Active
75%
Likely Yes
82% agreement
Aug 31, 2026
IG: 0.48

Will SMMT insiders remain net buyers (zero dispositions) through H1 2026?

Active
75%
Likely Yes
84% agreement
Jul 15, 2026
IG: 0.48

Will Summit confirm FDA-validated US manufacturing capability for ivonescimab by PDUFA date?

Active
48%
Likely No
78% agreement
Nov 30, 2026
IG: 0.48

Resolution Timeline

Jul 15, 2026
Will SMMT insiders remain net buyers (zero dispositions) through H1 2026?
Prediction: 75%
Aug 31, 2026
Will Summit Therapeutics maintain at least 4 quarters of cash runway through Q2 2026?
Prediction: 75%
Sep 30, 2026
Will HARMONi-3 squamous interim PFS analysis report statistically significant results by Q3 2026?
Prediction: 60%
Oct 15, 2026
Will SMMT maintain a market capitalization above $10B through September 2026?
Prediction: 55%
Nov 14, 2026
Will Summit report interim OS data from HARMONi-3 before the November 14 PDUFA date?
Prediction: 52%
Nov 30, 2026
Will the FDA approve ivonescimab (HARMONi BLA) by the November 14, 2026 PDUFA date?
Prediction: 32%
Nov 30, 2026
Will Summit confirm FDA-validated US manufacturing capability for ivonescimab by PDUFA date?
Prediction: 48%